Oncimmune’s EarlyCDT Lung blood test featured on ITV News

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has noted the national ITV News1 feature last weekend on Oncimmune’s EarlyCDT® Lung blood test titled “New Blood Test Provides Breakthrough in Lung Cancer Detection Rates”.

The news feature highlighted that, in the UK, more than 35,000 people die of lung cancer each year and most have their lung cancer diagnosed late thereby lowering their chances of survival. Oncimmune’s pioneering new lung cancer blood test enables lung cancer to be detected early which means clinicians can treat the disease and save lives.

Oncimmune’s technology focuses on identifying the immune system’s response to the presence of lung cancer. The body produces antibodies which, if detected by Oncimmune’s blood test, enables clinicians to focus their diagnosis on identifying the disease and treating it earlier than current clinical practice.

The news article noted that Oncimmune’s EarlyCDT Lung blood test has received a Medtech Innovation Briefing (“MIB”) from the UK’s National Institute for Health and Care Excellence (“NICE”). NICE reviewed EarlyCDT Lung for cancer risk stratification of indeterminate pulmonary nodules (“IPNs”). The briefing, intended to support NHS commissioners and staff who are considering using new medical or diagnostic technologies, states that EarlyCDT Lung enables earlier and accurate diagnosis of lung cancer in high risk patients which could mean intervention is offered early, with the potential benefit of early treatment and improved outcomes. The MIB also notes that this could have a wider benefit by saving other NHS resources (CT scanning and radiologists) and reducing waiting times.

The ITV news report concluded by saying that “the test has been recommended for use in the NHS and, if given full approval, many more patients could benefit from screening for this deadly disease.”

Adam M Hill, CEO of Oncimmune said: “We are delighted that Oncimmune’s EarlyCDT Lung blood test has received such international publicity. The benefits of offering patients the opportunity to identify lung cancer early are clear – early detection of this disease saves lives. We are actively engaged across the NHS to bring the blood test to clinicians and patients.”

1 https://www.itv.com/news/2020-08-08/new-blood-test-provides-breakthrough-in-lung-cancer-detection-rates

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    X
    LinkedIn

    More articles like this

    Fintel plc

    Fintel core revenue growth is higher than Zeus forecast

    Fintel plc (LON:FNTL), the leading provider of Fintech and support services to the UK retail financial services sector, has released a trading update for the six months to 30 June 2022, which reveals: Core revenue grew

    OnTheMarket Plc

    OnTheMarket analyst Zeus confident in forecasts

    Foxtons, one of London’s leading estate agencies with more than 50 interconnected branches across London, has signed an agreement to advertise its UK residential sales and letting properties at OnTheMarket plc (LON:OTMP). Zeus view: Foxtons, the

    SpaceandPeople analyst Zeus restores estimates and valuation

    SpaceandPeople plc (LON:SAL) secures, sells, and manages flexible space for brand experiences, short term promotions and retailing in high footfall venues for its customers, including in shopping centres and travel hubs. The Group has issued a

    Lookers Plc

    Lookers shares are still undervalued says Zeus

    Lookers plc (LON:LOOK) has released an H1 trading update reporting a continuation of strong performance year to date. H1 2022 underlying PBT is expected to be c. £45m and Management anticipate full year PBT will also

    Inchcape

    Inchcape performance exceeding expectations says Zeus

    Inchcape plc (LON:INCH) has released another positive trading update, with performance exceeding expectations so far this year. This follows on from a positive Q1 update on 28 April. Through quarterly improvement in Distribution volumes and operating

    boohoo Plc

    Boohoo Group analyst Zeus sees a strong performance in Q1

    ¨ Q1 financial highlights: Boohoo Group plc (LON:BOO) revenue of £445.7m is -8.3% YOY vs. a strong comp (Q1 FY22 revenue +32.1%), in line with Zeus’s forecast and management’s previously stated guidance. Gross sales growth remained